ReviewCurrent urology reports2026
Management of Lower Urinary Tract Symptoms in Patients on Active Surveillance for Prostate Cancer.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewLower urinary tract symptoms (LUTS) are highly prevalent among ageing men and frequently coexist with low- and favorable-intermediate-risk prostate cancer. As the adoption of active surveillance (AS) increases and surveillance duration lengthens, clinicians are increasingly required to manage bothersome LUTS without compromising oncologic monitoring or future definitive treatment options. This review synthesizes contemporary evidence regarding the epidemiology, evaluation, and management of LUTS in men undergoing AS. RECENT
findingsEmerging data demonstrate that medical and surgical therapies for benign prostatic hyperplasia (BPH) can be safely implemented in carefully selected men on AS. Contemporary evidence clarifies the impact of BPH therapies on prostate-specific antigen (PSA) interpretation, multiparametric MRI performance, biopsy feasibility, and candidacy for subsequent definitive prostate cancer treatment. Accumulating studies suggest that appropriately selected interventions aimed at improving bladder outlet obstruction do not adversely affect oncologic outcomes or compromise surveillance protocols. Management of LUTS in men undergoing AS requires a nuanced understanding of how BPH therapies interact with cancer surveillance strategies. Current evidence supports timely and individualized treatment of bothersome LUTS, including surgical management when indicated, without deferring intervention solely due to AS status. Thoughtful integration of symptom control and oncologic monitoring optimizes both quality of life and long-term cancer care.
Indexed as
Identifiers
41813844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.